Published Date: 04/10/2013
Category: Therapies & Markets
Antibody Drug Conjugates or ADCs are a new class of therapeutic agents that combine the advantages of potent cytotoxic agents with selective targeting of a monoclonal antibody. Two ADCs have been approved Seattle Genomics/Takeda’s Adcetris (2011) and Roche’s Kadcyla (2013) - this has stimulated considerable investment in the field.
Table of Contents
1.      Case Study: The withdrawal of Pfizer’s Mylotarg, 2010
The ADC Market: Historic Challenges
Recent Developments in the ADC Market
2.      Recent FDA and EMA Approvals
Development of Stable Platforms for ADC
Adcetris drives market growth, 2012
Rapid growth of Kadcyla in first-half 2013
3.      ADC Platform Technology
4.      Emerging Players
5.      Ambrx ADC Technology
6.      CytomX Probody Technology
7.      Key Pipeline Highlights:
Leading products of commercial interest include:
8.      Inotuzumab ozogamicin (Pfizer)
9.      SAR3419 (Sanofi)
10.  PSMA-ADC (Progenic)